CHAPTER 1 EXECUTIVE SUMMARY 2
Key findings 2
Introduction to the PharmaVitae Universe 4
Industry coverage of the PharmaVitae Universe 4
The PharmaVitae forecast database 4
The PharmaVitae peer sets 5
PharmaVitae operating cost and profit forecasts 6
Strategic overview of the PharmaVitae Universe to 2013 6
Overview of the PharmaVitae Universe outlook to 2013 8
The company outlook to 2013 10
PharmaVitae Universe launch/core/expiry analysis 15
PharmaVitae Universe molecule type analysis 20
PharmaVitae Universe M&A analysis 23
PharmaVitae Universe operating performance analysis 25

CHAPTER 2 THE BIG PHARMA OUTLOOK TO 2013 30
Key findings 30
Overview of Big Pharma to 2013 31
Big Pharma Rx pharma sales performance, 2001-13 31
Big Pharma landscape, 2007-13 33
Big Pharma company analysis 35
Big Pharma company sales, 2007 36
Big Pharma company sales outlook, 2007-13 37
Big Pharma launch/core/expiry analysis 41
Big Pharma therapy area analysis 45
Big Pharma molecule type analysis 49
Big Pharma operating performance analysis 54

CHAPTER 3 THE MID PHARMA OUTLOOK TO 2013 57
Key findings 57
Overview of Mid Pharma to 2013 58
Mid Pharma Rx pharma sales performance, 2001-13 58
Mid Pharma landscape, 2007-13 59
Mid Pharma company analysis 61
Mid Pharma launch/core/expiry analysis 67
Mid Pharma therapy area analysis 71
Mid Pharma molecule type analysis 74
Mid Pharma operating performance analysis 79

CHAPTER 4 THE BIOTECH OUTLOOK TO 2013 82
Key findings 82
Overview of Biotech to 2013 83
Biotech Rx pharma sales performance, 2001-13 83
Biotech landscape, 2007-13 84
Biotech company analysis 85
Biotech launch/core/expiry analysis 91
Biotech therapy area analysis 95
Biotech molecule type analysis 98
Biotech operating performance analysis 103

CHAPTER 5 THE JAPAN PHARMA OUTLOOK TO 2013 106
Key findings 106
Overview of Japan Pharma to 2013 107
Japan Pharma Rx pharma sales performance, 2001-13 107
Japan Pharma landscape, 2007-13 108
Japan Pharma company analysis 110
Japan Pharma launch/core/expiry analysis 116
Japan Pharma therapy area analysis 120
Japan Pharma molecule type analysis 123

CHAPTER 6 APPENDIX 128
References 128
Datamonitor reports 128
Other references 128
General references 128
Abbreviations 128
Exchange rates 129

List of Tables
Table 1: Strategic overview of the PharmaVitae Universe, 2007-13 6
Table 2: PharmaVitae Universe overview by peer set, 2007-13 10
Table 3: Launch/core/expiry analysis (percentage of 2001 sales), 2001-07 17
Table 4: Launch/core/expiry analysis (percentage of 2007 sales), 2007-13 17
Table 5: PharmaVitae Universe operating performance ($ billion), 2007-13 28
Table 6: Big Pharma peer set overview, 2007-13 35
Table 7: Big Pharma launch/core/expiry portfolios, 2007-13 43
Table 8: Mid Pharma peer set overview, 2007-13 61
Table 9: Mid Pharma launch/core/expiry portfolios, 2007-13 69
Table 10: Biotech peer set overview, 2007-13 85
Table 11: Biotech launch/core/expiry portfolios, 2007-13 93
Table 12: Japan Pharma peer set overview, 2007-13 110
Table 13: Japan Pharma launch/core/expiry portfolios, 2007-13 118
Table 14: Exchange rates, 2007 129

List of Figures
Figure 1: PharmaVitae Universe Rx sales ($bn) and year-on-year growth rate (%), 2001-13 8
Figure 2: PharmaVitae Universe Rx sales ($bn) by company, 2007 12
Figure 3: PharmaVitae Universe Rx sales CAGR (%) by company, 2007-13 13
Figure 4: PharmaVitae Universe Rx sales ($bn) by company, 2013 14
Figure 5: PharmaVitae Universe launch/core/expiry analysis, change in sales ($bn), 2001-07 and 2007-13 15
Figure 6: PharmaVitae Universe launch/core/expiry analysis, change in sales (% 2007) by peer set, 2007-13 18
Figure 7: PharmaVitae Universe launch/core/expiry analysis, change in sales (% 2007) by company, 2007-13 19
Figure 8: PharmaVitae Universe Rx sales ($bn) by molecule type, 2001-13 20
Figure 9: PharmaVitae Universe Rx sales growth ($bn) by molecule type, 2007-13 21
Figure 10: PharmaVitae Universe company-by-company Rx sales growth ($bn) by molecule type, 2007-13 22
Figure 11: PharmaVitae Universe Rx sales growth ($bn) by source, 2001-07 23
Figure 12: PharmaVitae Universe operating performance ($bn), 2001-13 25
Figure 13: PharmaVitae Universe operating performance (% total sales), 2001-13 26
Figure 14: PharmaVitae Universe operating profit growth drivers ($bn), sales vs. operating costs, 2001-07 and 2007-13 27
Figure 15: Big Pharma peer set Rx sales and growth rate, 2001-13 31
Figure 16: Big Pharma peer set landscape, 2007-13 33
Figure 17: Big Pharma peer set companies, Rx sales ($m), 2007 36
Figure 18: Big Pharma peer set companies, Rx sales CAGR (%), 2007-13 37
Figure 19: Big Pharma peer set companies, Rx sales ($bn), 2007-13 38
Figure 20: Big Pharma peer set companies, Rx sales ($m), 2013 38
Figure 21: Big Pharma peer set growth by source of product ($m), 2001-07 39
Figure 22: Big Pharma peer set launch/core/expiry, 2001-13 41
Figure 23: Big Pharma companies launch/core/expiry ($bn), 2007-13 42
Figure 24: Big Pharma companies launch/core/expiry (percentage of 2007 Rx sales), 2007-13 44
Figure 25: Big Pharma peer set, therapy area focus, 2001-13 45
Figure 26: Big Pharma company sales by therapy area ($m), 2007 46
Figure 27: Big Pharma company sales by therapy area ($m), 2013 47
Figure 28: Big Pharma peer set, molecule type focus, 2001-13 49
Figure 29: Big Pharma peer set growth by molecule type, 2007-13 50
Figure 30: Big Pharma companies molecule type focus (% Rx sales), 2007 51
Figure 31: Big Pharma companies, growth by molecule type, 2007-13 52
Figure 32: Big Pharma companies molecule type focus (% Rx sales), 2013 53
Figure 33: Big Pharma operating performance ($bn), 2001-13 54
Figure 34: Big Pharma operating performance (% total sales), 2001-13 55
Figure 35: Big Pharma companies operating performance ($m), 2007-13 56
Figure 36: Mid Pharma peer set Rx sales and growth rate, 2001-13 58
Figure 37: Mid Pharma peer set landscape, 2007-13 59
Figure 38: Mid Pharma peer set companies, Rx sales ($m), 2007 62
Figure 39: Mid Pharma peer set companies, Rx sales CAGR (%), 2007-13 63
Figure 40: Mid Pharma peer set companies, Rx sales ($bn), 2007-13 64
Figure 41: Mid Pharma peer set companies, Rx sales ($m), 2013 65
Figure 42: Mid Pharma peer set growth by source of product ($m), 2001-07 66
Figure 43: Mid Pharma peer set launch/core/expiry, 2001-13 67
Figure 44: Mid Pharma companies launch/core/expiry ($bn), 2007-13 68
Figure 45: Mid Pharma companies launch/core/expiry (percentage of 2007 Rx sales), 2007-13 70
Figure 46: Mid Pharma peer set, therapy area focus, 2001-13 71
Figure 47: Mid Pharma company sales by therapy area ($m), 2007 72
Figure 48: Mid Pharma company sales by therapy area ($m), 2013 73
Figure 49: Mid Pharma peer set, molecule type focus, 2001-13 74
Figure 50: Mid Pharma peer set growth by molecule type, 2007-13 75
Figure 51: Mid Pharma companies molecule type focus (% Rx sales), 2007 76
Figure 52: Mid Pharma companies, growth by molecule type, 2007-13 77
Figure 53: Mid Pharma companies molecule type focus (% Rx sales), 2013 78
Figure 54: Mid Pharma operating performance ($bn), 2001-13 79
Figure 55: Mid Pharma operating performance (% total sales), 2001-13 80
Figure 56: Mid Pharma companies operating performance ($m), 2007-13 81
Figure 57: Biotech peer set Rx sales and growth rate, 2001-13 83
Figure 58: Biotech peer set landscape, 2007-13 84
Figure 59: Biotech peer set companies, Rx sales ($m), 2007 86
Figure 60: Biotech peer set companies, Rx sales CAGR (%), 2007-13 87
Figure 61: Biotech peer set companies, Rx sales ($bn), 2007-13 88
Figure 62: Biotech peer set companies, Rx sales ($m), 2013 89
Figure 63: Biotech peer set growth by source of product ($m), 2001-07 90
Figure 64: Biotech peer set launch/core/expiry, 2001-13 91
Figure 65: Biotech companies launch/core/expiry ($bn), 2007-13 92
Figure 66: Biotech companies launch/core/expiry (percentage of 2007 Rx sales), 2007-13 94
Figure 67: Biotech peer set, therapy area focus, 2001-13 95
Figure 68: Biotech company sales by therapy area ($m), 2007 96
Figure 69: Biotech company sales by therapy area ($m), 2013 97
Figure 70: Biotech peer set, molecule type focus, 2001-13 98
Figure 71: Biotech peer set growth by molecule type, 2007-13 99
Figure 72: Biotech companies molecule type focus (% Rx sales), 2007 100
Figure 73: Biotech companies, growth by molecule type, 2007-13 101
Figure 74: Biotech companies molecule type focus (% Rx sales), 2013 102
Figure 75: Biotech operating performance ($bn), 2001-13 103
Figure 76: Biotech operating performance (% total sales), 2001-13 104
Figure 77: Biotech companies operating performance ($m), 2007-13 105
Figure 78: Japan Pharma peer set Rx sales and growth rate, 2001-13 107
Figure 79: Japan Pharma peer set landscape, 2007-13 108
Figure 80: Japan Pharma peer set companies, Rx sales ($m), 2007 111
Figure 81: Japan Pharma peer set companies, Rx sales CAGR (%), 2007-13 112
Figure 82: Japan Pharma peer set companies, Rx sales ($bn), 2007-13 113
Figure 83: Japan Pharma peer set companies, Rx sales ($m), 2013 114
Figure 84: Japan Pharma peer set growth by source of product ($m), 2001-07 115
Figure 85: Japan Pharma peer set launch/core/expiry, 2001-13 116
Figure 86: Japan Pharma companies launch/core/expiry ($bn), 2007-13 117
Figure 87: Japan Pharma companies launch/core/expiry (percentage of 2007 Rx sales), 2007-13 119
Figure 88: Japan Pharma peer set, therapy area focus, 2001-13 120
Figure 89: Japan Pharma company sales by therapy area ($m), 2007 121
Figure 90: Japan Pharma company sales by therapy area ($m), 2013 122
Figure 91: Japan Pharma peer set, molecule type focus, 2001-13 123
Figure 92: Japan Pharma peer set growth by molecule type, 2007-13 124
Figure 93: Japan Pharma companies molecule type focus (% Rx sales), 2007 125
Figure 94: Japan Pharma companies, growth by molecule type, 2007-13 126
Figure 95: Japan Pharma companies molecule type focus (% Rx sales), 2013 127